Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole, Quetiapine, and Ziprasidone in First Episode Psychosis
NCT02305823Phase 4Completed
- Sponsor
- Fundación Marqués de Valdecilla
- Start
- Oct 2005
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in schizophrenia and psychotic disorders comparing Aripiprazole, Quetiapine and Ziprasidone (3 arms). Primary endpoint: Effectiveness of antipsychotics (percentage of discontinuation of the initially assigned treatment) at 6 weeks. Started Oct 2005; status: completed.
02
Drugs
aripiprazolequetiapineziprasidone
03
Conditions
schizophreniapsychotic disorders
Beyond the preview
Go deeper on NCT02305823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305823.